Sana Biotechnology has bought central nervous system therapy developer and portfolio company Oscine, which is founded on University of Rochester research.

Oscine Therapeutics, a US-based brain disease drug developer spun out of University of Rochester Medical Center, was acquired in September 2020 by cell therapy developer Sana Biotechnology for $8.5m. Oscine’s cell therapy platform has been developed to treat brain and central nervous system (CNS) diseases including Alzheimer’s and multiple sclerosis. It focuses on leveraging the…

The rest of this content is only accessible to University Venturing: News, Data, and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.